| Literature DB >> 27713260 |
Taku Obara1,2, Takayoshi Ohkubo3,4, Michihiro Satoh5, Nariyasu Mano6, Yutaka Imai7.
Abstract
Appropriate control of blood pressure (BP) is essential for prevention of future cardiovascular events. However, BP control among treated hypertensive patients has been insufficient. Recently, the usefulness of self-measured BP at home (home BP measurement) for the management of hypertension has been reported in many studies. We evaluated BP control both at home and in the office among treated hypertensive patients in primary care settings in Japan (the J-HOME study). We found poor control of home and office BPs and clarified some factors affecting control. We also examined factors associated with the magnitude of the white-coat effect, the morning-evening BP difference, and home heart rate in this J-HOME study.Entities:
Keywords: antihypertensive treatment; home blood pressure; hypertension
Year: 2010 PMID: 27713260 PMCID: PMC4033918 DOI: 10.3390/ph3020419
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Characteristics of study subjects.
| Age (years) | 66.2±10.5 |
| Women (%) | 55.2 |
| Body mass index (kg/m2) | 23.8±3.3 |
| Current smoker (%) | 14.2 |
| Current drinker (%) | 34.8 |
| History of cerebrovascular disease (%) | 16.7 |
| History of ischemic heart disease (%) | 8.2 |
| Diabetes mellitus (%) | 13.7 |
| Renal disease (%) | 5.1 |
| Dyslipidemia (%) | 40.2 |
| High uric acid (%) | 11.5 |
| Morning home systolic BP (mmHg) | 139.6±13.8 |
| diastolic BP (mmHg) | 81.7±9.6 |
| heart rate (bpm) | 67.2±9.1 |
| Evening home systolic BP (mmHg) | 133.7±13.4 |
| diastolic BP (mmHg) | 76.9±9.2 |
| heart rate (bpm) | 69.6±9.2 |
| Office systolic BP (mmHg) | 142.8±14.4 |
| diastolic BP (mmHg) | 80.7±9.4 |
BP, blood pressure; Values are shown as mean ± SD for continuous variables.
Antihypertensive treatment.
| Duration of treatment (months) | 29.6±42.8 |
| Number of drugs, mean (n) | 1.7±0.9 |
| 1 (%) | 48.7 |
| 2 (%) | 35.4 |
| 3 (%) | 12.3 |
| 4 or more (%) | 3.6 |
| Class of drugs (including combination therapy) (%) | |
| Calcium-channel blockers | 69.6 |
| Amlodipine | 38.9 |
| Dihydropyridines other than amlodipine | 30.2 |
| Non_ dihydropyridines | 1.6 |
| Angiotensin II receptor blockers | 43.6 |
| Angiotensin converting-enzyme inhibitors | 16.7 |
| Diuretics | 9.3 |
| Alpha-blockers | 13.4 |
| Beta-blockers | 11.7 |
| Alpha/beta-blockers | 3.8 |
Values are shown as mean ± SD for continuous variables.